A 50-year-old male patient with comorbid human immunodeficiency virus developed a relapse of bipolar disorder after a switch from oral aripiprazole 10 mg/day to intramuscular aripiprazole depot 200 mg every 28 days plus oral aripiprazole 5 mg/day. The patient was concomitantly taking ...
(www.tcpdf.org) Patient Preference and Adherence 2013:7 Dovepress Depot aripiprazole for schizophrenia Performance scale,64 did not change compared with baseline in aripiprazole-treated patients, but declined significantly in placebo-treated patients.65 How would clinicians use, and what could one ...
All patients with depot formulations (N = 15) were included in the >10 mg/day group. c Young adults: age 16–24 years; adults: age 25–64 years; elderly: age 65–82 years. d International Classification of Diseases-10: organic disorders, anxiety, personality disorder, intellectual ...
“Platform of the World Health Organisation”. For search terms see webappendix 1. The last search was performed in April 2016. We also researched the medical reviews that pharmaceutical companies submitted to the FDA and we inquired with the providers ofpaliperidone palmitateand risperidone depot (...
Do no substitute IM long-acting depot suspension formulations Vial Reconstitute lyophilized power with sterile water for injection (SWI); discard any unused portion of diluent 400 mg/vial: 1.9 mL SWI 300 mg/vial: 1.5 mL SWI Final concentration for either vial is 200 mg/mL following reconstitutio...
Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2012;73:617–624. 21. Gopal S, Hough DW, Xu H, et al. Efficacy and safety of paliperidone palmitate in adult ...
Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week multicenter, randomized, double-blind placebo-controlled study J. Clin. Psychiatry, 73 (5) (2012), pp. 617-624 View in ScopusGoogle Scholar Kay et al., 1987 S. Kay, A. Fiszbein, L. Opler ...
The objective of this study was to investigate the physicochemical properties, drug release and in situ depot-forming behavior of alginate hydrogel containing poorly water-soluble aripiprazole (ARP) for achieving free-flowing injectability, clinically accessible gelation time and sustained drug release. Th...